Ophthalmic Steroids Drugs Market, Size, Share, Growth, Trends, Insight and Industry Forecast, 2021-2028

SKU: DMPH3618 | Last Updated On: Aug 31 2021 | No. of Pages: 180 | Available Formats

> Global Ophthalmic Steroids Drugs Market Expected to reach at a high CAGR by 2028: DataM Intelligence

Global Ophthalmic Steroids Drugs Market is segmented By Disease (Retinal Disorders, Eye Allergy, Uveitis, Others), By Dosage Form (Eye Drops, Eye Solutions, Ointments), By Distribution Channel (Hospital pharmacies, Online pharmacies, Clinics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

Market Overview

The Ophthalmic Steroids Drugs Market The size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028). 

Ophthalmic corticosteroids (cortisone-like medicines) are drugs which are used to prevent permanent damage to the eye that may occur with certain eye problems. They provide relief from redness, irritation, and other discomforts of the eye.

Source: DataM Intelligence Analysis (2020)

Market Dynamics

An increase in the prevalence of intraocular disorders and increased incidence of diabetes mellitus leading to diabetes retinopathy will increase the Ophthalmic Steroids Drugs Market

An increase in the prevalence of intraocular disorders will drive the ophthalmic steroids drugs market in the forecast period

Glaucoma is an eye disease which is associated with elevated intraocular pressure, in which damage to the eye  nerve can lead to loss of vision and even blindness. It is the leading cause of irreversible blindness in the world which usually shows no symptoms early in its course. Glaucoma can only be diagnosed by regular eye check-ups. Intraocular pressure increases in the eye when either too much fluid is produced or the drainage or outflow channels of the eye become blocked. Steroids are used widely in ophthalmology to suppress inflammation, reduce symptoms and minimize scarring. They are prescribed as drops, creams, ointments and rarely tablets. They are also injected into and around the eye, most recently as depot preparations. Injected depot intraocular steroids have been reported to have a 63% incidence of adverse effects. Ocular side effects include cataracts, raised intraocular pressure, and suppression of the immune response make infection more likely and delay wound healing.

Glaucoma poses a significant public health concern as it is the second leading cause of blindness after cataracts, and this blindness is usually irreversible. It is estimated that 57.5 million people worldwide are affected by primary open-angle glaucoma (POAG).

An increase in the incidence of diabetes mellitus leading to diabetic retinopathy will drive the ophthalmic steroids drugs market

Diabetes mellitus, also called diabetes, is a term for several conditions involving how body turns food into energy. When a perosn eats a carbohydrate, the body turns it into a sugar called glucose and sends that to the bloodstream. Diabetic retinopathy is one of the diabetes complication that affects the eyes. It is caused by the  damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). At first, diabetic retinopathy might cause no symptoms or only mild vision problems.

The global diabetes prevalence in 2019 is estimated to be 9.3% (463 million people), rising to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The prevalence is higher in urban (10.8%) than rural (7.2%) areas and in high-income (10.4%) than low-income countries (4.0%). There are around 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide.

Side effects associated with ophthalmic steroids drugs will hamper the market

There are four important ocular side effects of corticosteroids: steroid-induced glaucoma, cataract formation, delayed wound healing, and increased susceptibility to infection. Children of less than two years of age may be susceptible to the effects of ophthalmic corticosteroids which may increase the chance of side effects. If this medicine has been ordered for a young child, it should be discussed with the doctor.

Pred Forte (prednisolone acetate ophthalmic suspension) is a steroid which is used to treat eye swelling caused by infection, allergy, injury, surgery or other conditions. Pred Forte is available in generic form. Side effects of Pred Forte are uncommon and may include itching,irritation stinging,burning of the eyes for 1 to 2 minutes ,temporary cloudy vision, increased sensitivity to light, visual disturbance (blurry vision), irritation in the eye, and allergic reactions when the medication is applied.

COVID-19 Impact Analysis

COVID-19 had a negative impact on the Ophthalmic Steroids Drugs Market With the demand for COVID-19 vaccines, the demand for ophthalmic steroids drugs has decreased its manufacturing. But with the government lifting the bans and industries opening up their manufacturing units, the ophthalmic steroids drugs market will increase.

Market Segment Analysis

The retinal Disorders segment dominated the ophthalmic steroids drugs market

A new compound, developed by Sylentis a biotechnology company  penetrates into the retina to treat age-related macular degeneration and diabetic retinopathy with the administration of ophthalmic drops. Regeneron Pharmaceuticals announced that the FDA had approved EYLEA (aflibercept) to treat all stages of diabetic retinopathy. In the U.S. it is estimated that eight million people have diabetic retinopathy, and is one of the cause of blindness among working-age adults. The approval was based on the PANORAMA trial results, a one-year phase 3 trial involving 402 patients at varying stages of diabetic retinopathy. The results were impressive — 80% of patients receiving EYLEA every eight weeks showed significant signs of improvement, compared to just 15% in the control group.

Beovu®, a treatment for wet age-related macular degeneration (AMD) newly approved by the US Food and Drug Administration (FDA), often provides similar vision benefits to Eylea® when administered every three months. Eylea is frequently administered every two months. Hence, with increased drug approvals for retinal disorders, this segment will dominate the market.

Eye drops segment dominated the market

Prednisolone eye drops are used to treat short-term inflammatory eye conditions which are usually prescribed by an eye specialist. They contain a corticosteroid which helps to relieve inflammation, redness, and irritation. Eye drops are used to soothe various eye problems. Purposes range from giving moisture to the eyes to correcting glaucoma or pink eye. There are several other reasons for using eye drops as medicines.

FDA approves topical corticosteroids for the treatment of dry eye disease. The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% for short-term treatment of the signs and symptoms of dry eye disease. The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis, Kala Pharmaceuticals Inc.)

The hospital pharmacies segment will dominate the ophthalmic steroids drugs market

Prednisolone is a steroid medicine used to relieve the redness, itching, and swelling caused by eye infections and other conditions. Prednisolone 0.12% and 1% are available only with a doctor's prescription—availability of trained doctors at hospitals and easily accessible pharmacy. To avoid self-medication and misuse of drugs, a hospital pharmacy is best where a patient can visit the doctor and purchase the medication.

Source: DataM Intelligence Analysis (2020)

Ophthalmic Steroids Drugs Market Geographical Analysis

North America region will dominate the ophthalmic steroids drugs market

The presence of high healthcare infrastructure, high consumer awareness, and increased incidence of intraocular disorders will drive the market in this region.

Due to an overall aging population, the number of people with visual impairment and blindness is increasing. While initiatives like Healthy People 2020 Vision aim to improve visual health by reducing visual impairment and blindness in the United States. In United States by 2050, an estimated 7.32 million people will have POAG, with the highest number among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. The CDC estimates that 4.1 million Americans are affected with diabetic retinopathy, and nearly 900,000 Americans are threatened with vision-damaging retinopathy.

Alcon, the global leader in eye care announced Pataday Once Daily Relief Extra Strength(olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo®, has been approved by the Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the United States.

Competitive Landscape

Major key players in the ophthalmic steroids drugs market are Bausch & Lomb Inc., Alimera Sciences, Allergan, Inc., Novartis AG, GlaxoSmithKline plc, Genentech, Inc., Pfizer Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc. Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.

Ophthalmic Steroids Drugs MarketKey Companies to Watch

Novartis AG

Overview: As a leading global medicines company, Novartis is reimagining medicine to improve and extend people's lives. Novartis uses digital technologies and innovative science to create transformative treatments in areas of great medical need. In their quest to find new medicines, they consistently top among the world's best companies investing in research and development. Their products reach nearly 1 billion people globally, and are finding innovative ways to expand access to the latest treatments. Around 125 000 people of more than 140 nationalities work at Novartis across the world.

Product Portfolio: The company focuses on Research, Innovation, Quality, Sustainability, innovative medicines, generic medicines, and biosimilars, a global leader in eye care, unique portfolio focuses & broad healthcare portfolio, Cell & Gene Therapy, and Data & Digital.

Key Development: On June 11, 2020, Novartis announced that the US Food and Drug Administration (FDA) had approved a label update for Beovu® (brolucizumab) to include additional safety information regarding retinal vasculitis and retinal vascular occlusion.

Why Purchase the Report?

  • Visualize the composition of the Ophthalmic Steroids Drugs Market segmentation By Disease, By Dosage Form and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in Ophthalmic Steroids Drugs Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Ophthalmic Steroids Drugs Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The Ophthalmic Steroids Drugs Market report would provide an access to an approx. 60 market data table, 52  figures and 200 pages. 

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

 

Market Segmentation

Ophthalmic Steroids Drugs Market - By Disease

  • Retinal Disorders
  • Eye Allergy
  • Uveitis
  • Others

Ophthalmic Steroids Drugs Market - By Dosage Form

  • Eye Drops
  • Eye Solutions
  • Ointments

Ophthalmic Steroids Drugs Market - By Distribution Channel

  • Hospital pharmacies
  • Online pharmacies
  • Clinics

Ophthalmic Steroids Drugs Market - By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Table of Contents

  1. Ophthalmic Steroids Drugs Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Ophthalmic Steroids Drugs Market – Market Definition and Overview

  3. Ophthalmic Steroids Drugs Market – Executive Summary

    1. Market Snippet By Disease
    2. Market Snippet By Dosage Form
    3. Market Snippet By Distribution Channel
  4. Ophthalmic Steroids Drugs Market – Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. An increase in the prevalence of intraocular disorders will drive the ophthalmic steroids drugs market in the forecast period
        2. An increase in the incidence of diabetes mellitus leading to diabetic retinopathy will drive the ophthalmic steroids drugs market
      2. Restraints:
        1. Side effects associated with ophthalmic steroids drugs will hamper the market
      3. Opportunity
      4. Impact Analysis
  5. Ophthalmic Steroids Drugs Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Epidemiology Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Regulatory Analysis
    6. Reimbursement Analysis
    7. Unmet Needs
  6. Ophthalmic Steroids Drugs Market – COVID-19 Analysis

    1. Analysis of Covid-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
    2. Pricing Dynamics Amid Covid-19
    3. Demand-Supply Spectrum
    4. Government Initiatives Related to the Market During Pandemic
    5. Manufacturers Strategic Initiatives
    6. Conclusion 
  7. Ophthalmic Steroids Drugs Market – By Disease

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Segment
      2. Market Attractiveness Index, By Disease Segment
    2. Retinal Disorders*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Eye Allergy
    4. Uveitis
    5. Others
  8. Ophthalmic Steroids Drugs Market – By Dosage Form

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
      2. Market Attractiveness Index, By Dosage Form
    2. Eye Drops*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Eye Solutions
    4. Ointments
  9. Ophthalmic Steroids Drugs Market – By Distribution Channel

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
      2. Market Attractiveness Index, By Distribution Channel Segment
    2. Hospital pharmacies *
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Online pharmacies
    4. Clinics
  10. Ophthalmic Steroids Drugs Market – By Region

    1. Introduction
      1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11. Ophthalmic Steroids Drugs Market – Competitive Landscape

    1. Key Developments and Strategies
    2. Company Share Analysis
    3. Product Benchmarking
    4. List of Key Companies to Watch
    5. List of Company with disruptive technology
    6. List of Start Up Companies
  12. Ophthalmic Steroids Drugs Market- Company Profiles

    1. Novartis AG*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Bausch & Lomb Inc
    3. Alimera Sciences
    4. Fresenius Kabi AG
    5. GlaxoSmithKline plc
    6. Genentech, Inc.
    7. Pfizer Inc.
    8. Shanghai Pharmaceutical Group Co., Ltd.
    9. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
    10. China Resources Pharmaceutical GroupCo., Ltd(*LIST NOT EXHAUSTIVE)
  13. Ophthalmic Steroids Drugs Market – DataM  

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

List of Tables

Table 01 Ophthalmic Steroids Drugs Market Value, By Disease, 2020, 2024 & 2028($ Million)

Table 02 Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2020, 2024 & 2028($ Million)

Table 03 Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2020, 2024 & 2028($ Million)

Table 04 Ophthalmic Steroids Drugs Market Value, By Disease, 2020, 2024 & 2028($ Million)

Table 05 Ophthalmic Steroids Drugs Market Value, By Disease, 2018-2028 ($ Million)

Table 06 Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2020, 2024 & 2028($ Million)

Table 07 Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2018-2028 ($ Million)

Table 08 Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2020, 2024 & 2028($ Million)

Table 09 Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2018-2028 ($ Million)

Table 10 Ophthalmic Steroids Drugs Market Value, By Region, 2020, 2024 & 2028($ Million)

Table 11  Ophthalmic Steroids Drugs Market Value, By Region, 2018-2028 ($ Million)

Table 12 North America Ophthalmic Steroids Drugs Market Value, By Disease, 2018-2028 ($ Million)

Table 13 North America Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2018-2028 ($ Million)

Table 14 North America Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2018-2028 ($ Million)

Table 15 North America Ophthalmic Steroids Drugs Market Value, By Country, 2018-2028 ($ Million)

Table 16 South America Ophthalmic Steroids Drugs Market Value, By Disease, 2018-2028 ($ Million)

Table 17  South America Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2018-2028 ($ Million)

Table 18 South America Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2018-2028 ($ Million)

Table 19 South America Ophthalmic Steroids Drugs Market Value, By Country, 2018-2028 ($ Million)

Table 20 Europe Ophthalmic Steroids Drugs Market Value, By Disease, 2018-2028 ($ Million)

Table 21 Europe Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2018-2028 ($ Million)

Table 22 Europe Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2018-2028 ($ Million)

Table 23 Europe Ophthalmic Steroids Drugs Market Value, By Country, 2018-2028 ($ Million)

Table 24 Asia-Pacific Ophthalmic Steroids Drugs Market Value, By Disease, 2018-2028 ($ Million)

Table 25 Asia-Pacific Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2018-2028 ($ Million)

Table 26 Asia-Pacific Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2018-2028 ($ Million)

Table 27 Asia-Pacific Ophthalmic Steroids Drugs Market Value, By Country, 2018-2028 ($ Million)

Table 28 Middle East & Africa Ophthalmic Steroids Drugs Market Value, By Disease, 2018-2028 ($ Million)

Table 29 Middle East & Africa Ophthalmic Steroids Drugs Market Value, By Dosage Form, 2018-2028 ($ Million)

Table 30 Middle East & Africa Ophthalmic Steroids Drugs Market Value, By Distribution Channel, 2018-2028 ($ Million)

Table 31 Novartis AG: Overview

Table 32 Novartis AG: Product Portfolio

Table 33 Novartis AG: Key Developments

Table 34 Bausch & Lomb Inc: Overview

Table 35 Bausch & Lomb Inc: Product Portfolio

Table 36 Bausch & Lomb Inc: Key Developments

Table 37 Alimera Sciences: Overview

Table 38 Alimera Sciences: Product Portfolio

Table 39 Alimera Sciences: Key Developments

Table 40 Fresenius Kabi AG: Overview

Table 41 Fresenius Kabi AG: Product Portfolio

Table 42 Fresenius Kabi AG: Key Developments

Table 43 GlaxoSmithKline plc: Overview

Table 44 GlaxoSmithKline plc: Product Portfolio

Table 45 GlaxoSmithKline plc: Key Developments

Table 46          Genentech, Inc.: Overview

Table 47 Genentech, Inc.: Product Portfolio

Table 48 Genentech, Inc.: Key Developments

Table 49 Pfizer Inc. Overview

Table 50 Pfizer Inc.: Product Portfolio

Table 51 Pfizer Inc.: Key Developments

Table 52 Shanghai Pharmaceutical Group Co., Ltd.: Overview

Table 53 Shanghai Pharmaceutical Group Co., Ltd.: Product Portfolio

Table 54 Shanghai Pharmaceutical Group Co., Ltd.: Key Developments

Table 55 Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.: Overview

Table 56 Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.: Product Portfolio

Table 57 Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.: Key Developments

Table 58 China Resources Pharmaceutical GroupCo., Ltd: Overview

Table 59 China Resources Pharmaceutical GroupCo., Ltd: Product Portfolio

Table 60 China Resources Pharmaceutical GroupCo., Ltd: Key Developments

List of Figures

Figure 01 Ophthalmic Steroids Drugs Market Share, By  Type, 2020 & 2028(%)

Figure 02 Ophthalmic Steroids Drugs Market Share, By Dosage Form, 2020 & 2028(%)

Figure 03 Ophthalmic Steroids Drugs Market Share, By Distribution Channel, 2020 & 2028(%)

Figure 04 Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 05 Ophthalmic Steroids Drugs Market Y-o-Y Growth, By  Type, 2020-2028 (%)

Figure 06 Retinal Disorders: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 07 Eye Allergy: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 08          Uveitis : Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 09 Others : Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 10 Ophthalmic Steroids Drugs Market Y-o-Y Growth, By Dosage Forms, 2020-2028 (%)

Figure 11 Eye Drops: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 12 Eye Solutions: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 13 Ointments: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 14 Ophthalmic Steroids Drugs Market Y-o-Y Growth, By Distribution Channel, 2020-2028 (%)

Figure 15 Hospital pharmacies: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 16 Online pharmacies: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 17 Clinics: Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

 

Figure 18 Ophthalmic Steroids Drugs Market Y-o-Y Growth, By Region, 2020-2028 (%)

Figure 19 North America Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 20 North America Ophthalmic Steroids Drugs Market Share, By Disease, 2020 & 2028(%)

Figure 21 North America Ophthalmic Steroids Drugs Market Share, By Dosage Form, 2020 & 2028(%)

Figure 22 North America Ophthalmic Steroids Drugs Market Share, By Distribution Channel, 2020 & 2028(%)

Figure 23 North America Ophthalmic Steroids Drugs Market Share, By Country, 2020 & 2028(%)

Figure 24 South America Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 25 South America Ophthalmic Steroids Drugs Market Share, By Disease, 2020 & 2028(%)

Figure 26 South America Ophthalmic Steroids Drugs Market Share, By Dosage Form, 2020 & 2028(%)

Figure 27 South America Ophthalmic Steroids Drugs Market Share, By Distribution Channel, 2020 & 2028(%)

Figure 28 South America Ophthalmic Steroids Drugs Market Share, By Country, 2020 & 2028(%)

Figure 29 Europe Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 30 Europe Ophthalmic Steroids Drugs Market Share, By Disease, 2020 & 2028(%)

Figure 31 Europe Ophthalmic Steroids Drugs Market Share, By Dosage Form, 2020 & 2028(%)

Figure 32 Europe Ophthalmic Steroids Drugs Market Share, By Distribution Channel, 2020 & 2028(%)

Figure 33 Europe Ophthalmic Steroids Drugs Market Share, By Country, 2020 & 2028(%)

Figure 34 Asia-Pacific Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 35 Asia-Pacific Ophthalmic Steroids Drugs Market Share, By Disease, 2020 & 2028(%)

Figure 36 Asia-Pacific Ophthalmic Steroids Drugs Market Share, By Dosage Form, 2020 & 2028(%)

Figure 37 Asia-Pacific Ophthalmic Steroids Drugs Market Share, By Distribution Channel, 2020 & 2028(%)

Figure 38 Asia-Pacific Ophthalmic Steroids Drugs Market Share, By Country, 2020 & 2028(%)

Figure 39 Middle East & Africa Ophthalmic Steroids Drugs Market Value, 2018-2028 ($ Million)

Figure 40 Middle East & Africa Ophthalmic Steroids Drugs Market Share, By Disease, 2020 & 2028(%)

Figure 41 Middle East & Africa Ophthalmic Steroids Drugs Market Share, By Dosage Form, 2020 & 2028(%)

Figure 42 Middle East & Africa Ophthalmic Steroids Drugs Market Share, By Distribution Channel, 2020 & 2028(%)

Figure 43 Novartis AG: Financials

Figure 44 Bausch & Lomb Inc: Financials

Figure 45 Alimera Sciences: Financials

Figure 46 Fresenius Kabi AG: Financials

Figure 47 GlaxoSmithKline plc: Financials

Figure 48 Genentech, Inc.: Financials

Figure 49 Pfizer Inc. Financials

Figure 50 Shanghai Pharmaceutical Group Co., Ltd.: Financials

Figure 51 Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.: Financials

Figure 52 China Resources Pharmaceutical GroupCo., Ltd: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your free sample proposal with a single click!

linkedinpinterest